111 related articles for article (PubMed ID: 22680928)
1. Molecular and clinical analysis of predictive biomarkers in non-small-cell lung cancer.
Passaro A; Palazzo A; Trenta P; Mancini ML; Morano F; Cortesi E
Curr Med Chem; 2012; 19(22):3689-700. PubMed ID: 22680928
[TBL] [Abstract][Full Text] [Related]
2. Molecular alterations in non-small cell lung carcinomas of the young.
VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
[TBL] [Abstract][Full Text] [Related]
3. Molecular testing and personalized treatment of lung cancer.
Sampsonas F; Ryan D; McPhillips D; Breen DP
Curr Mol Pharmacol; 2014; 7(1):22-32. PubMed ID: 25563851
[TBL] [Abstract][Full Text] [Related]
4. MET and ALK as targets for the treatment of NSCLC.
Capelletti M; Gelsomino F; Tiseo M
Curr Pharm Des; 2014; 20(24):3914-32. PubMed ID: 24138716
[TBL] [Abstract][Full Text] [Related]
5. The Utility of Thyroid Transcription Factor 1 (TTF-1), Napsin A, Excision Repair Cross-Complementing 1 (ERCC1), Anaplastic Lymphoma Kinase (ALK) and the Epidermal Growth Factor Receptor (EGFR) Expression in Small Biopsy in Prognosis of Patients with Lung Adenocarcinoma - A Retrograde Single-Center Study from Croatia.
Piljić Burazer M; Mladinov S; Ćapkun V; Kuret S; Glavina Durdov M
Med Sci Monit; 2017 Jan; 23():489-497. PubMed ID: 28128193
[TBL] [Abstract][Full Text] [Related]
6. Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer.
Sacco JJ; Al-Akhrass H; Wilson CM
Curr Pharm Des; 2016; 22(28):4374-85. PubMed ID: 27262325
[TBL] [Abstract][Full Text] [Related]
7. The value of biomarkers in patients with sarcomatoid carcinoma of the lung: molecular analysis of 33 cases.
Jiang X; Liu Y; Chen C; Zhan Z; Yan Q; Guo Y; Wang Q; Li K
Clin Lung Cancer; 2012 Jul; 13(4):288-96. PubMed ID: 22169481
[TBL] [Abstract][Full Text] [Related]
8. New strategies for targeting the therapy of NSCLC: the role of ERCC1 and TS.
Ceppi P; Papotti M; Scagliotti G
Adv Med Sci; 2010; 55(1):22-5. PubMed ID: 20494871
[TBL] [Abstract][Full Text] [Related]
9. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
10. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
11. Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities.
Daga A; Ansari A; Patel S; Mirza S; Rawal R; Umrania V
Asian Pac J Cancer Prev; 2015; 16(10):4147-56. PubMed ID: 26028064
[TBL] [Abstract][Full Text] [Related]
12. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
13. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
14. [EGFR gene copy number, ERCC1 and BRCA1 protein expression and their relationship in non-small cell lung cancer].
Deng QH; Qiu Y; Mo MC; Zhang X; Xiong XG; Jiang M; He P; Wen DP; Zheng GX; He JX
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):508-12. PubMed ID: 22093627
[TBL] [Abstract][Full Text] [Related]
15. Predictive markers in lung cancer: a few hints for the practicing pathologist.
Barbareschi M; Barberis M; Buttitta F; Doglioni C; Fiorentino M; Fontanini G; Franco R; Marchetti A; Rossi G; Troncone G
Pathologica; 2018 Mar; 110(1):29-38. PubMed ID: 30259911
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.
Pelosi G; Gasparini P; Conte D; Fabbri A; Perrone F; Tamborini E; Pupa SM; Ciravolo V; Caserini R; Rossi G; Cavazza A; Papotti M; Nakatani Y; Maisonneuve P; Pastorino U; Sozzi G
J Thorac Oncol; 2016 May; 11(5):718-728. PubMed ID: 26804638
[TBL] [Abstract][Full Text] [Related]
17. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS.
Guisier F; Salaün M; Lachkar S; Lamy A; Piton N; Obstoy B; Sabourin JC; Thiberville L
Respirology; 2016 May; 21(4):718-26. PubMed ID: 27099101
[TBL] [Abstract][Full Text] [Related]
20. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]